Adamas Pharmaceuticals Inc.’s chief medical officer (CMO) Rajiv Patni told BioWorld that a full development program “just like one would do for a new chemical entity [NCE]” gets credit for the strong label – touting efficacy even during patients’ “off” times – for Gocovri (amantadine extended-release capsules), cleared by the FDA last week for levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD).